Atypical Parkinsonian Syndromes: A General Neurologists Perspective
Eur J Neurol 25:41-58, Deutschlander, A.B.,et al, 2018
Facial Bradykinesia
JNNP 84:681-685, Bologna, M.,et al, 2013
Incidence and Pathology of Synucleinopathies and Tauopathies Related to Parkinsonism
JAMA Neurol 70:859-866, Savica, R.,et al, 2013
Morning Glory Sign: A Particular MR Finding in Progressive Supranuclear Palsy
Magn Reson Med Sci 3:125-132, Adachi, M., et al, 2004
Diffusion-Weighted Imaging Discriminates Progressive Supranuclear Palsy from PD, But Not From the Parkinson Variant of Multiple System Atrophy
Neurol 60:922-927, Seppi,K.,et al, 2003
Improved Accuracy of Clinical Diagnosis of Lewy Body Parkinson's Disease
Neurol 57:1497-1499, Hughes,A.J.,et al, 2001
Magnetic Resonance Imaging-Based Volumetry Differentiates Idiopathic Parkinson's Syndrome from Multiple System Atrophy and Progressive Supranuclear Palsy
Ann Neurol 45:65-74, Schulz,J.B.,et al, 1999
Prevalence of Progressive Supranuclear Palsy and Multiple System Atrophy:A Cross-Sectional Study
Lancet 354:1771-1775, Schrag,A.,et al, 1999
What is the Accuracy of the Clinical Diagnosis of Multiple System Atrophy
Arch Neurol 54:937-944, Litvan,I.,et al, 1997
Some Specific Clinical Features Differentiate Multiple System Atrophy (Striatonigral Variety) from Parkinson's Disease
Arch Neurol 52:294-298, Colosimo,C.,et al, 1995
Parkinsonism-Recognition and Differential Diagnosis
BMJ 310:447-452, Quinn,N., 1995
Diff Diag of parkinson's Disease, Multiple Sys Atrophy, & Steele-Richardson-Olszewski Syndrome:Striatal F-Dopa PET Data
JNNP 57:278-284, Burn,D.J.,et al, 1994
Multiple System Atrophy & Prog Supranuc Palsy, Dimin Striatal D2 Dopamine Receptor Act by SPECT
Arch Neurol 50:513-516, vanRoyen,E.,et al, 1993
Clinicopath Conf
progressive Supranuclear Palsy, Case 46-1993, NEJM 329:1560-1567993., , 1993
Criteria for the Diagnosis of Corticobasal Degeneration
Neurol 80:496-503, Armstrong, M.J.,et al, 2013
Advances in Progressive Supranuclear Palsy: New Diagnostic Criteria, Biomarkers, and Therapeutic Approaches
Lancet Neurol 16:552-563, Boxer, A.L.,et al, 2017
Functional Impairment in Progressive Supranuclear Palsy
Neurol 80:380-384, Duff, K.,et al, 2013
Progressive Supranuclear Palsy: A Current Review
The Neurologist 14:79-88, Lubarsky,M. &Juncos,J.L., 2008
New and Reliable MRI Diagnosis for Progressive Supranuclear Palsy
Neurol 64:2050-2055, Oba,H.,et al, 2005
Clinicopath Conf
Progressive Supranuclear Palsy, Case 26, 1997, NEJM 337:549-55697., , 1997
Apolipoprotein E Genotype in Diverse Neurodegenerative Disorders
Ann Neurol 38:131-135, Schneider,J.A.,et al, 1995
Eye Movements in Parkinsonian Syndromes:Vidailhet
M. , et al, Neurol 35:420-42694., , 1994
Autonomic Nervous Function in Progressive Supranuclear Palsy
Arch Neurol 48:1083-1084, vanDijk,J.G.,et al, 1991
MR Imaging in Progressive Suupranuclear Palsy and Shy-Drager Syndrome
J Comput Assist Tomogr 13:555-560, Savoiardo,M.,et al, 1989
Progressive Supranuclear Palsy & a Multi-Infarct State
Neurol 37:570-576, Dubinsky,R.M.&Jankovic,J., 1987
An 81-Year-Old Man with Imbalance and Memory Impairment
, Golbe,L.I.,et al,
Involuntary Groaning Induced by Levodopa Therapy in a Patient With Progressive Supranuclear Palsy
JAMA Neurol 77:1569, Park, J.E., 2020
Degenerative Diseases of the Nervous System, Progressive Supranuclear Palsy
Adams & Victors Principles of Neurology, Chp 39, pg 1096, Ropper, A.H.,et al, 2014
Tau Forms in CSF as a Reliable Biomarker for Progressive Supranuclear Palsy
Neurol 71:1796-1803, Borroni,B.,et al, 2008
Clinical Features and Natural Histry of Progressive Supranuclear Palsy, A Clinical Cohort Study
Neurol 60:910-916, Nath,W.,et al, 2003
Cholinergic Vesicular Transporters in Progressive Supranuclesar Palsy
Neurol 58:1013-1018,997, Suzuki,M.,et al, 2002
Computerized Posturography Analysis of Progressive Suprnuclear Palsy
Arch Neurol 57:1464-1469, Ondo,W.,et al, 2000
Zolpidem in Progressive Supranuclear Palsy
NEJM 341:543-544, Daniele,A.,et al, 1999
Progressive Supranuclear Palsy, A Survey of the Disease Course
Neurol 50:1637-1647, Santacruz,P.,et al, 1998
Pharmacological Therapy in Progressie Supranuclear Palsy
Arch Neurol 55:1099-1102, Kompoliti,K.,et al, 1998
Proton Magnetic Resonance Spectroscopy in Parkinson's Disease and Progressive Supranuclear Palsy
JNNP 62:239-242, Federico,F.,et al, 1997
Presymptomatic Hypertension is a Major Feature in the Diagnosis of Progressive Supranuclear Palsy
Arch Neurol 54:1104-1108, Ghika,J.&Bogousslavsky,J., 1997
Characterizing Swallowing Abnormalities in Progressive Supranuclear Palsy
Neurol 48:1654-1662, Litvan,I.,et al, 1997
Natural History of Progressive Supranuclear Palsy & Clin Predictors of Survival:A Clinicopath Study
JNNP 61:615-620, Litvan,I.,et al, 1996
Neuropsychiatric Aspects of Progressive Supranuclear Palsy
Neurol 47:1184-1189, Litvan,I.,et al, 1996
Botulinum Toxin-A Improves the Rigidity of Progressive Supranuclear Palsy
Ann Neurol 35:237-239, Polo,K.B.&Jabbari,B., 1994
Progressive Supranuclear Palsy:Neuropathologic and Clinical Heterogeneity
Neurol 44:1015-1024, Gearing,M.,et al, 1994
The Syndrome of'Pure Akinesia'and Its Relationship to Progressive Supranuclear Palsy
Neurol 44:1025-1029, Riley,D.E.,et al, 1994
Preliminary NINDS Neuropathologic Criteria for Steele-Richardson-Olszewski Syndrome (Progressive Supranuclear Palsy)
Neurol 44:2015-2019, Hauw,J.-J., 1994
Olfactory Testing Differentiates Between Progressive Supranuclear Palsy & Idiopathic Parkinson's Dis
Neurol 43:962-965, Doty,R.L.,et al, 1993
Striatal D2 Receptor Status in Patients with Parkinson's Disease, Striatonigral Degeneration, and PSP, (PET)
Ann Neurol 31:184-192, Brooks,D.J.,et al, 1992
Idazoxan Treatment in Progressive Supranuclear Palsy
Neurol 41:986-991, Ghika,J.,et al, 1991
Positron Emission Tomography in Progressive Supranuclear Palsy
Arch Neurol 48:389-391, Bhatt,M.H.,et al, 1991
The Apomorphine Test in Parkinsonian Syndromes
JNNP 54:870-872, D'Costa,D.F.,et al, 1991